Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies

Author:

Schneeweiss Andreas1,Hartkopf Andreas D.2,Müller Volkmar3,Wöckel Achim4,Lux Michael P.5,Janni Wolfgang6,Ettl Johannes7,Belleville Erik8,Huober Jens6,Thill Marc9,Fasching Peter A.10,Kolberg Hans-Christian11,Pöschke Patrik10,Welslau Manfred12,Overkamp Friedrich13,Tesch Hans14,Fehm Tanja N.15,Lüftner Diana16,Schütz Florian17

Affiliation:

1. National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital and German Cancer Research Center, Heidelberg, Germany

2. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany

3. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

4. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

5. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany

6. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

7. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

8. ClinSol GmbH & Co KG, Würzburg, Germany

9. Agaplesion Markus Krankenhaus, Frauenklinik, Frankfurt, Germany

10. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

11. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

12. Onkologie Aschaffenburg, Aschaffenburg, Germany

13. OncoConsult Overkamp GmbH, Berlin, Germany

14. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany

15. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

16. Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany

17. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany

Abstract

AbstractThis review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynecology

Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3